42P Real-life data on treatment with poly (ADP-ribose) polymerase inhibitor (iPARP), in patients over 65 years of age with ovarian cancer: A current need

Abstract

BackgroundIPARPs are the latest advance in ovarian cancer treatment and have been shown and have been shown in clinical trials to be an effective and safe treatment. The increase in life expectancy implies an increase in the age of the patients treated, so the development of effective drugs with few adverse effects is becoming more important every day. The objective of the study was to establish the clinical and toxicity differences of iPARP treatment between patients older and younger than 65 years.MethodsA retrospective, single-center study was conducted. All patients diagnosed of high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer treated with iPARPs between 2017 and 2021 in Puerta de Hierro Hospital were included. Epidemiological and clinical data were registered.ResultsTable: 42PCharacteristics<65 years (41)>65 years (19)Comorbidities:HypertensionDiabetesHypercholesterolemiaIschemic eventHeart failure7.3%2.4%14.6%2.4%0%26.3%10.5%21.0%0%5.26%Smoking habitCurrentFormer14.6%29.3%1%36.8%Stage at diagnosisI-II: 14.6%III-IV: 86.4%I-II: 15.8III-IV: 84.4%Toxicity (any)43.9%63.2%p=0.165Grade >G314.6%5.3%P=0.293ToxicityGastrointestinalCardiologicalHematologicalOthers:33%22.2%33.4%5.5%50%25%21%4%Median treatment duration (months)11.57Discontinuation:9.8%21.0%P= 0.231Delays:9.8%15.8%P=0.498Subsequent treatment68.2%71.4%P=0.333 Open table in a new tab ConclusionsPatients >65 years treated with iPARPs did not experience higher rates of adverse events or treatment interruptions/discontinuations. iPARPs should be a valid treatment option for ovarian cancer in this increasingly frequent subgroup of patients.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. BackgroundIPARPs are the latest advance in ovarian cancer treatment and have been shown and have been shown in clinical trials to be an effective and safe treatment. The increase in life expectancy implies an increase in the age of the patients treated, so the development of effective drugs with few adverse effects is becoming more important every day. The objective of the study was to establish the clinical and toxicity differences of iPARP treatment between patients older and younger than 65 years. IPARPs are the latest advance in ovarian cancer treatment and have been shown and have been shown in clinical trials to be an effective and safe treatment. The increase in life expectancy implies an increase in the age of the patients treated, so the development of effective drugs with few adverse effects is becoming more important every day. The objective of the study was to establish the clinical and toxicity differences of iPARP treatment between patients older and younger than 65 years. MethodsA retrospective, single-center study was conducted. All patients diagnosed of high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer treated with iPARPs between 2017 and 2021 in Puerta de Hierro Hospital were included. Epidemiological and clinical data were registered. A retrospective, single-center study was conducted. All patients diagnosed of high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer treated with iPARPs between 2017 and 2021 in Puerta de Hierro Hospital were included. Epidemiological and clinical data were registered. ResultsTable: 42PCharacteristics<65 years (41)>65 years (19)Comorbidities:HypertensionDiabetesHypercholesterolemiaIschemic eventHeart failure7.3%2.4%14.6%2.4%0%26.3%10.5%21.0%0%5.26%Smoking habitCurrentFormer14.6%29.3%1%36.8%Stage at diagnosisI-II: 14.6%III-IV: 86.4%I-II: 15.8III-IV: 84.4%Toxicity (any)43.9%63.2%p=0.165Grade >G314.6%5.3%P=0.293ToxicityGastrointestinalCardiologicalHematologicalOthers:33%22.2%33.4%5.5%50%25%21%4%Median treatment duration (months)11.57Discontinuation:9.8%21.0%P= 0.231Delays:9.8%15.8%P=0.498Subsequent treatment68.2%71.4%P=0.333 Open table in a new tab ConclusionsPatients >65 years treated with iPARPs did not experience higher rates of adverse events or treatment interruptions/discontinuations. iPARPs should be a valid treatment option for ovarian cancer in this increasingly frequent subgroup of patients. Patients >65 years treated with iPARPs did not experience higher rates of adverse events or treatment interruptions/discontinuations. iPARPs should be a valid treatment option for ovarian cancer in this increasingly frequent subgroup of patients.